🟢 CALC rebounds after sharp decline driven by FDA review of KOURAGE trial data and private placement financing

CalciMedica (CALC) shares declined significantly during the regular session following announcements regarding the FDA's review of its Phase 2 KOURAGE trial data and a private placement financing of up to approximately $49 million. The stock plummeted -25.64% to close at $0.60 after the company announced the FDA allowed dosing to continue in its KOURAGE trial and secured financing to advance its pulmonary hypertension program. CALC is now trading at $0.63 (+6.29%) in after-hours, staging a technical rebound.